Glioblastoma Market Research Report - Global Forecast till 2027

Global Glioblastoma Market: Information by Type (Primary Glioblastoma and Secondary Glioblastoma), by Treatment (Surgical Procedure, Radiation Therapy, Chemotherapy and others), by End User (Hospitals, Specialty Clinics & Centers and others) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/HC/6835-CR | September 2019 | Region: Global | 133 pages

Please note that the assessment period of report has been updated from 2018-2025 to 2020-2027. Cordially fill the sample form for updated data.

Market Overview

Global Glioblastoma Market is expected to register a CAGR of
7.40% to reach 1,643.4 million by 2025. Glioblastoma is a type of brain tumor. The increasing occurrences of glioblastoma, a type of brain tumor, coupled with extensive research in glioblastoma treatment, and the rising adoption of chemotherapy are expected to fuel the growth of the global glioblastoma market. However, the high cost of drugs and the failure of drug candidates in clinical trial phases are anticipated to hamper the market growth.


Market Dynamics


The increasing incidence rate of glioblastoma is expected to fuel the growth of the global glioblastoma market. According to the statistics published in 2017 by the National Centre for Biotechnology Information (NCBI), glioblastoma has an incidence rate of 3.19 per 100,000 persons in the US. The growing prevalence indirectly increases the healthcare expenditure of the people as well as the government. This motivates the players operating in the market to come up with alternatives for the treatment of glioblastoma. Thus, this is likely to fuel the growth of the global glioblastoma market during the forecast period.


Global Glioblastoma Market Share, by End User, 2018 (%)  Glioblastoma Market


Source: MRFR Analysis


Segmentation


The global glioblastoma market has been segmented by type, treatment, and end user. The market, based on type, has been bifurcated into primary glioblastoma and secondary glioblastoma. Based on treatment, the glioblastoma market has been segregated into surgical procedure, radiation therapy, chemotherapy, and others. The global glioblastoma market, based on end user, has been divided into hospitals, specialty clinics and centers, and others. The specialty clinics and centers held a share of 36.8% in 2018.


Western Europe Glioblastoma Market Share, 2018 (%)  Glioblastoma Market


Source: MRFR Analysis


Regional Analysis


The global glioblastoma market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


The Americas is likely to dominate the global glioblastoma market. The growth in this region can be attributed to the increased cases of glioblastoma and brain tumors. Moreover, the approval of drugs helps in maximizing the growth of the market in this region.


Europe held a substantial share in the global glioblastoma market. This can be attributed to a large number of clinical trials in the region. For instance, Merck KGaA along with Vaximm GmbH is involved in Phase I and II trials to evaluate the efficacy and safety of VXM01 in combination with Avelumab in patients with resectable and non-resectable progressive glioblastoma following tumor resection and radio-chemotherapy containing temozolomide.


Asia-Pacific is estimated to be the fastest-growing region in the global market. The rise in the improved healthcare infrastructure promises a high level of research on the treatment of glioblastoma in the region.


The glioblastoma market in the Middle East & Africa is expected to witness a modest market growth rate from 2019 to 2025. The Middle East would lead the market growth in this region. Rising awareness regarding health and availability of new treatment methods are expected to drive the market growth during the assessment period.


Key Players


The prominent players in the global glioblastoma market are F. Hoffmann-La Roche Ltd (Switzerland), Arbor Pharmaceuticals, LLC (US), Merck & Co., Inc. (US), Sun Pharmaceutical Industries Ltd (India), Amgen Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel).


Some of the key strategies followed by players operating in the global glioblastoma market were innovation, product development, and acquisition & mergers.



  • In May 2019, Merck entered into a definitive agreement to acquire Peloton Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company, focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases.



  • In January 2018, Amgen and Allergan PLC received the approval by the European Commission (EC) for the marketing authorization of MVASI for the treatment of glioblastoma as well as certain types of cancers.



  • In November 2016, Sun Pharma acquired Biosintez, a Russian pharmaceutical company engaged in the manufacturing and marketing of pharmaceutical products.


Market Segmentation


Global Glioblastoma Market, by Type



  • Primary Glioblastoma

  • Secondary Glioblastoma


Global Glioblastoma Market, by Treatment



  • Surgical Procedure

  • Radiation Therapy

  • Chemotherapy

  • Others


Global Glioblastoma Market, by End User



  • Hospitals

  • Specialty Clinics and Centers

  • Others


Global Glioblastoma Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Available Additional Customizations



  • Mega Trends in the Market

  • Glioblastoma Market: Challenges


Intended Audience



  • Pharmaceutical companies

  • Contract research manufacturing organizations

  • Research & development organizations

  • Academic institutes



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2025: USD 1,643.4 Million
  • 2027: Significant value
  •   CAGR   7.40%(2018-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   By Type, By Treatment , By End User and By Region
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   F. Hoffmann-La Roche Ltd (Switzerland), Arbor Pharmaceuticals, LLC (US), Merck & Co., Inc. (US), Sun Pharmaceutical Industries Ltd (India), Amgen Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel)
      Key Market Opportunities

  • The high cost of drugs.
  • The failure of drug candidates in clinical trial phases.
  •   Key Market Drivers   The increasing occurrences of glioblastoma, a type of brain tumor, coupled with extensive research in glioblastoma treatment.


    Frequently Asked Questions (FAQ) :


    glioblastoma market is expected to reach a valuation of USD 1.6 billion by 2025.

    The global market is expected to exhibit a strong 7.4% CAGR over the forecast period from 2019 to 2025.

    The growing prevalence of glioblastoma is the major driver for the global market.

    The Americas are likely to dominate the global glioblastoma market.

    Leading players in the market include F. Hoffman-La Roche, Merck, and Amgen, among others.



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.